ASX Announcements Archive 2012
17 Dec 2012
Change of Director’s Interest Notice
read more >>
11 Dec 2012
Open Briefing interview with MD & CEO Robert Klupacs
read more >>
21 Nov 2012
Change of Director's Interest Notice
read more >>
20 Nov 2012
Results of Annual General Meeting 20 November 2012
read more >>
20 Nov 2012
CEO AGM Presentation to shareholders
read more >>
20 Nov 2012
CEO AGM Presentation to Shareholders
read more >>
15 Nov 2012
Circadian grants world-wide licence to Bio-Rad to market research products
read more >>
08 Nov 2012
VGX-100 Poster Presentation at EORTC
read more >>
08 Nov 2012
VGX-100 Poster Presentation at EORTC
read more >>
07 Nov 2012
VGX-100 Top 10 Oncology Candidate Windhover Conference
read more >>
02 Nov 2012
AusBiotech Presentation Company Update
read more >>
22 Oct 2012
Annual Report / Notice of AGM and Proxy
read more >>
02 Oct 2012
Dr Errol Malta – Resignation as Director
read more >>
24 Sep 2012
Open Briefing - FY2012 Results and Outlook
read more >>
24 Aug 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
read more >>
23 Aug 2012
Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012
read more >>
17 Jul 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
read more >>
12 Jul 2012
Change of Director’s Interest Notice
read more >>
10 Jul 2012
Change of Director’s Interest Notice
read more >>
09 Jul 2012
Alpha Securities Analyst Investment Research Report Available on Circadian Website
read more >>
07 Jul 2012
Bio 2012 - Building a Diagnostics Franchise
read more >>
22 Jun 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
read more >>
12 Jun 2012
Circadian makes $1M Share Placement
read more >>
12 Jun 2012
Reinstatement to Official Quotation
read more >>
27 Apr 2012
Notice of Ceasing to be a Substantial Holder
read more >>
02 Apr 2012
Change of Director’s Interest Notice
read more >>
29 Mar 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
read more >>
15 Mar 2012
Analyst Investment Research Report Available on Circadian Website
read more >>
09 Mar 2012
Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test
read more >>
09 Mar 2012
Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of Unknown Primary
read more >>
20 Feb 2012
Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook
read more >>
16 Feb 2012
Half-Year Financial Report & Operational Achievements
read more >>
30 Jan 2012
VGX-100 identified as potential new therapy for improving corneal graft survival
read more >>
12 Jan 2012
CEO Presentation at Biotech Showcase San Francisco
read more >>
09 Jan 2012
Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients
read more >>
